Baricitinib Therapy in COVID-19
NCT04358614
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
COVID
Pneumonia
Interventions
DRUG:
Baricitinib 4 MG Oral Tablet
Sponsor
Fabrizio Cantini